MNOVNasdaq

MEDICINOVA INC

Healthcare·Oncology·Phase 2·La Jolla, CA, United States
OncologyNeurologyMetabolicRespiratoryGastroenterology

MEDICINOVA INC (MNOV): 4 pipeline candidates · 1 upcoming catalyst · ~24 mo cash runway · 4 clinical trials. Updated within the last hour.

6.8/10

BioSniper Score

5-factor signal · derived from public data

Cash Runway6.6

23.8 months

Financial Health9.9

D/E 0.08 · 0% dilution

Pipeline Maturity8.5

Lead: Phase 2/Phase 3

Pipeline Breadth7.2

4 candidates

Catalyst Momentum2.0

1 upcoming, next in ~653d

Insider SignalN/A

N/A

A transparent, data-derived signal for MEDICINOVA INCacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.

Key Financials

Market Cap

$61.5M

Cash

$27.3M

Quarterly Burn

$3.5M

Runway

23.8 mo

Revenue

$187K

Cash Runway vs Catalysts

Tracked catalysts land within the current projected cash runway.

Cash ends ~Jun 2028
Today~26 mo out
Catalyst within runway

Pipeline (4 candidates)

Upcoming Catalysts (1)

Institutional Holdings

Source: SEC Form 13F · as of Mar 2026

Institutional holders

29

Total value held

$7.9M

HolderSharesValue
vanguard capital management llc1,222,078$1.7M
essex woodlands management, inc.1,105,941$1.5M
blackrock, inc.705,954$967K
citigroup inc635,715$871K
geode capital management, llc543,843$745K
vanguard fiduciary trust co280,621$384K
state street corp193,698$265K
renaissance technologies llc189,900$260K
barclays plc162,900$223K
northern trust corp133,163$182K

Showing top 10 of 29 institutional holders of MEDICINOVA INC. Sign up for the full 13F holder list and quarter-by-quarter ownership history.

4 clinical trials·CEO: Dr. Yuichi Iwaki M.D., Ph.D.

Frequently asked questions

How many drug candidates are in MEDICINOVA INC's pipeline?

MEDICINOVA INC (MNOV) has 4 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.

What is MEDICINOVA INC's lead drug candidate?

MEDICINOVA INC's most advanced tracked candidate is mn-001 (Phase 2) for Diabetes Mellitus, Type 2; Idiopathic Pulmonary Fibrosis.

What is MEDICINOVA INC's next catalyst?

MEDICINOVA INC's next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Phase 2b/3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 12 Month Clinical Trial to" — expected April 1, 2028.

What is MEDICINOVA INC's cash runway?

Based on its most recent reported cash balance and quarterly burn rate, MEDICINOVA INC has approximately 23.8 months of cash runway.

What is MEDICINOVA INC's market capitalization?

MEDICINOVA INC's market capitalization is approximately $61.5M.

Get the full picture on MEDICINOVA INC

Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.